Dyne Therapeutics

Dyne Therapeutics is a biotechnology company focused on developing targeted therapies for patients with serious muscle diseases. They leverage their proprietary FORCE platform to create precision medicines aimed at addressing the underlying genetic causes of these conditions. Founded in 2018, Dyne Therapeutics has made significant strides in advancing its pipeline, particularly in the areas of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company generates revenue through strategic partnerships and funding rounds, positioning itself as a leader in the field of genetic medicine.

Recent Posts by Dyne Therapeutics

1-20 of 231